Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Jones

Neurology Chillicothe, OH Doctor of Osteopathy

NPI 1841226842 CMS profile 415577

272 Hospital Rd, Chillicothe, OH 45601

Open in the dashboard

General payments

$5,843

316 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Jones of Chillicothe, OH is reported in the CMS Open Payments database as having received $5,843 across 316 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,708 97
2024 General $1,032 66
2023 General $1,066 42
2022 General $404 21
2021 General $766 42
2020 General $403 27
2019 General $465 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Jones
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Michael Jones were reported at $1,708. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Michael Jones Neurology median Middle half National median
2019 $465 $474 $118–$2,177 $163
2020 $403 $367 $82–$2,309 $114
2021 $766 $438 $104–$2,547 $132
2022 $404 $442 $103–$2,388 $149
2023 $1,066 $464 $119–$2,312 $160
2024 $1,032 $468 $119–$2,323 $164
2025 $1,708 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $892 59 payments
  2. EMD Serono, Inc. $724 30 payments
  3. ACADIA Pharmaceuticals Inc $715 27 payments
  4. Biogen, Inc. $578 22 payments
  5. Neurocrine Biosciences, Inc. $495 39 payments
  6. SK Life Science, Inc. $484 28 payments
  7. Lilly USA, LLC $396 23 payments
  8. Teva Pharmaceuticals USA, Inc. $299 10 payments
  9. Amneal Pharmaceuticals LLC $296 21 payments
  10. UCB, Inc. $229 13 payments
  11. Other $734 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,734 310 payments
  2. Education $109 6 payments
Products named General payments · program years 2019–2025
  1. QULIPTA $841 53 payments
  2. UBRELVY $709 43 payments
  3. INGREZZA $495 39 payments
  4. NUPLAZID $413 11 payments
  5. TYSABRI $361 13 payments
  6. EMGALITY $294 19 payments
  7. Mavenclad $256 2 payments
  8. VUMERITY $227 10 payments
  9. CREXONT $204 15 payments
  10. REYVOW $194 13 payments
  11. Other $2,559 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

2,076

Median for Neurology: 833

Drug cost

$290,707

Median for Neurology: $202,670

Branded share of claims

25.8%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rebif Interferon Beta-1a/Albumin Brand 13 $137,655
Briviact Brivaracetam Brand 30 $29,754
Rytary Carbidopa/Levodopa Brand 32 $27,050
Emgality Pen Galcanezumab-Gnlm Brand 36 $25,340
Emgality Syringe Galcanezumab-Gnlm Brand 22 $18,023
Neupro Rotigotine Brand 13 $9,461
Carbamazepine Er Carbamazepine Brand 72 $7,628
Carbidopa-Levodopa Carbidopa/Levodopa Brand 193 $3,136
Rivastigmine Generic 14 $2,949
Primidone Generic 197 $2,605

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$40,703

Medicare's payments for the services billed

Medicare patients

293

Average age 71

Services billed

721

168 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 37%
Ischemic heart disease 32%
Depression 32%
COPD 26%
Chronic kidney disease 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $167
$167 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $163
$163 — —
UBRELVY
  • AbbVie, Inc. $154
$154 — —
Mavenclad
  • EMD Serono, Inc. $121
$121 — —
EMGALITY
  • Lilly USA, LLC $86
$86 58 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record